Sign In
Buy RXRX
$2.95
-0.0750 (-2.48%)
At Close: Jul 17, 2026
Why Recursion Pharmaceuticals (RXRX) Outpaced the Stock Market Today
06:51pm, Tuesday, 14'th Jul 2026
In the most recent trading session, Recursion Pharmaceuticals (RXRX) closed at $3.34, indicating a +1.21% shift from the previous trading day.
2 Beaten-Down Stocks That Still Aren't Worth Buying
04:30pm, Saturday, 11'th Jul 2026
Recursion Pharmaceuticals has yet to prove that its approach to developing medicines is superior. Sarepta Therapeutics will struggle to shake off safety concerns about its most important therapy.
Here's Why Recursion Pharmaceuticals (RXRX) Fell More Than Broader Market
06:51pm, Wednesday, 08'th Jul 2026
Recursion Pharmaceuticals (RXRX) closed the most recent trading day at $3.72, moving 3.13% from the previous trading session.
3 Cancer Stocks to Watch as Oncology Innovation Accelerates
09:35am, Wednesday, 08'th Jul 2026
Oncology innovation is reshaping cancer care as AI, immunotherapy and targeted therapies fuel pipeline growth and spotlight promising cancer-focused stocks.
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
06:03am, Sunday, 05'th Jul 2026
Two stocks that have fallen out of favor and one hot stock that was one of Thursday's biggest losers were on the Ark Invest founder's shopping list.
Dyne Therapeutics vs. Recursion Pharmaceuticals: Which Development Stage Pharma Stock Is a Better Buy in 2026?
09:21am, Saturday, 04'th Jul 2026
Dyne Therapeutics is advancing a clinical-stage platform specifically targeting genetically driven neuromuscular diseases. Recursion Pharmaceuticals utilizes an artificial intelligence OS to accelerat
Moderna vs. Recursion: Which Cutting-Edge Pharma Stock Is a Better Buy in 2026?
11:14am, Friday, 03'rd Jul 2026
Moderna is evolving from a COVID-19 vaccine specialist into a multi-product firm with major oncology and rare disease partnerships. Recursion Pharmaceuticals is leveraging artificial intelligence and
AI Is Transforming Drug Discovery. Here Is the Next Trillion-Dollar Biotech Opportunity
09:38am, Tuesday, 30'th Jun 2026
Artificial intelligence is reshaping nearly every industry, but some of its biggest opportunities are emerging far from Silicon Valley. Biotechnology has spent decades producing breakthrough medicines
Recursion Pharmaceuticals vs. Summit Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?
07:45am, Tuesday, 30'th Jun 2026
Recursion harnesses AI for large-scale drug discovery, while Summit's betting on a single oncology candidate. How do their financials and risk profiles stack up?
2 Beaten-Down Artificial Intelligence (AI) Stocks for Contrarian Investors to Consider Buying
12:15am, Friday, 26'th Jun 2026
Recursion Pharmaceuticals' approach to drug discovery could advance the industry. Fiverr is implementing a strategy shift that may help it bounce back from recent headwinds.
Recursion Pharmaceuticals (RXRX) Ascends While Market Falls: Some Facts to Note
06:50pm, Wednesday, 24'th Jun 2026
Recursion Pharmaceuticals (RXRX) closed at $3.23 in the latest trading session, marking a +2.22% move from the prior day.
Why Recursion Pharmaceuticals (RXRX) Dipped More Than Broader Market Today
06:51pm, Tuesday, 16'th Jun 2026
The latest trading day saw Recursion Pharmaceuticals (RXRX) settling at $3.18, representing a -3.34% change from its previous close.
Recursion Pharmaceuticals: Short-Trade Crowded But Near-Term Squeeze Not Guaranteed
12:43pm, Friday, 12'th Jun 2026
Recursion Pharmaceuticals, Inc. is advancing REC-1245, an RBM39 degrader, in the DHALIA trial in solid tumors, with Q1'26 earnings noting no dose-limiting toxicities so far. Initial DHALIA trial data
Recursion Pharmaceuticals (RXRX) Dips More Than Broader Market: What You Should Know
06:50pm, Wednesday, 10'th Jun 2026
Recursion Pharmaceuticals (RXRX) closed the most recent trading day at $3.06, moving 5.12% from the previous trading session.
Recursion Pharmaceuticals, Inc. (RXRX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
02:42pm, Tuesday, 09'th Jun 2026
Recursion Pharmaceuticals, Inc. (RXRX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
